A new study claims genetic tests available in the U. S. for detecting high risk of breast cancer may miss some mutations that indicate the disease. An additional test, available in Europe, but not the U. S., can detect gene changes the U. S. test can’t. The researchers say there are a lack of clinical testing options in the U. S., and inappropriate patent rules are stifling the development of new genetic screening methods.